Owkin: machine learning with privacy protection

Owkin deploys AI solutions using real-world data to optimize drug development while maintaining patient privacy

To better protect patient privacy in its machine learning-based analyses of real-world data for optimization of drug development and trial design, Owkin’s technology leaves patient data in the originating institutions.

Gilles Wainrib, Owkin’s co-founder and CSO, said that although drug development is often based on the analysis of small data sets from clinical trials, hospitals generate a large amount of real-world data that can be used to optimize drug development.

Hospitals, especially those in the U.S., do not want to share

Read the full 805 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE